Baron Funds, a renowned investment management company, recently published its third-quarter 2025 investor letter for the “Baron Health Care Fund.” The fund saw a 5.39% increase in value for its Institutional Shares during the quarter, slightly outperforming the Russell 3000 Health Care Index but falling short of the overall market represented by the Russell 3000 Index. The fund’s performance was driven by solid stock selection, although active sub-industry allocations and cash holdings had a negative impact as the market continued to rise.
One of the highlighted stocks in the investor letter was Boston Scientific Corporation (NYSE:BSX), a global leader in the manufacturing and marketing of medical devices in the MedSurg and Cardiovascular segments. Despite facing competition in the burgeoning pulsed field ablation (PFA) space for treating arrhythmia, Boston Scientific Corporation (NYSE:BSX) has continued to execute well with its Watchman device and PFA offerings. The stock showed a one-month return of 2.81% and a 52-week gain of 15.26%, closing at $98.59 per share on November 3, 2025, with a market capitalization of $146.154 billion.
Baron Health Care Fund’s assessment of Boston Scientific Corporation (NYSE:BSX) in the third quarter investor letter emphasized the company’s strong position in the medical device market. Despite facing competition from major players like Medtronic, Johnson & Johnson, and Abbott in the PFA space, Boston Scientific Corporation (NYSE:BSX) is seen as a strong compounder with a double-digit earnings per share growth profile. The company’s focus on cost discipline and margin expansion further solidifies its position within the large-cap medical device universe.
While Boston Scientific Corporation (NYSE:BSX) is not among the 30 most popular stocks among hedge funds, it remains an attractive investment option. The company reported a consolidated revenue of $5.065 billion in the third quarter of 2025, marking a 20.3% growth compared to the same period in 2024. Despite the potential of Boston Scientific Corporation (NYSE:BSX), some AI stocks offer greater upside potential with lower downside risk according to Baron Funds. Investors seeking undervalued AI stocks can explore opportunities in the market to maximize their returns.
In conclusion, Baron Health Care Fund’s third-quarter 2025 investor letter highlighted the performance and prospects of Boston Scientific Corporation (NYSE:BSX) as a key player in the medical device industry. While facing competition in specific segments, the company’s strong fundamentals and growth trajectory make it a compelling investment choice for the future. Investors are encouraged to conduct thorough research and consider their risk tolerance before making investment decisions in the dynamic healthcare sector.
